VA's $1.12B Pharmaceutical Prime Vendor Contract Awarded to McKesson Corporation for July 2025
Contract Overview
Contract Amount: $1,118,034,560 ($1.1B)
Contractor: Mckesson Corporation
Awarding Agency: Department of Veterans Affairs
Start Date: 2025-07-01
End Date: 2025-07-31
Sector: Healthcare
Official Description: EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2025 JULY
Plain-Language Summary
Department of Veterans Affairs obligated $1.12 billion to MCKESSON CORPORATION for work described as: EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2025 JULY Key points: 1. The Department of Veterans Affairs (VA) awarded a significant contract for pharmaceutical prime vendor services. 2. McKesson Corporation, a major player in pharmaceutical distribution, secured this substantial award. 3. The contract value highlights the critical need for reliable pharmaceutical supply chains within the VA. 4. This award represents a key component of the VA's healthcare infrastructure for the upcoming fiscal year.
Value Assessment
Rating: good
The contract value of $1.12 billion for a single month's services is substantial. Benchmarking against similar large-scale pharmaceutical distribution contracts would be necessary to fully assess pricing, but given McKesson's market position, the pricing is likely competitive.
Cost Per Unit: N/A
Competition Analysis
Competition Level: unknown
The contract type is a delivery order, suggesting it may be part of a larger indefinite-delivery/indefinite-quantity (IDIQ) contract. The specific competition method is not detailed, but for such a large and critical service, a competitive process is expected to ensure fair pricing and service quality.
Taxpayer Impact: The efficient procurement of pharmaceuticals ensures that veterans receive necessary medications, representing a direct and positive impact on taxpayer-funded healthcare services.
Public Impact
Ensures timely access to a wide range of prescription medications for veterans nationwide. Supports the VA's mission to provide comprehensive healthcare services to former service members. Contributes to the stability and efficiency of the VA's pharmaceutical supply chain. Potentially impacts drug pricing and availability across the broader healthcare market due to the scale of the contract.
Waste & Efficiency Indicators
Waste Risk Score: 50 / 10
Warning Flags
- Lack of detailed competition information.
- Potential for price fluctuations in pharmaceutical markets.
- Dependence on a single vendor for critical supplies.
Positive Signals
- Award to a well-established and experienced vendor.
- Significant contract value indicates robust demand and service provision.
- Supports a vital government healthcare program.
Sector Analysis
The pharmaceutical distribution sector is highly consolidated, with a few major players dominating the market. This contract falls within the healthcare services sector, specifically focusing on the logistics and distribution of medical supplies. Spending benchmarks for similar prime vendor contracts can vary widely based on the agency, scope, and duration.
Small Business Impact
The data does not indicate any specific set-asides for small businesses in this particular delivery order. Large prime vendor contracts in this sector are typically awarded to major corporations with extensive distribution networks, making direct participation by small businesses challenging, though they may be involved as subcontractors.
Oversight & Accountability
The Department of Veterans Affairs is responsible for overseeing this contract. Robust oversight mechanisms, including performance monitoring and compliance checks, are crucial to ensure McKesson Corporation meets the terms of the contract and provides high-quality pharmaceutical services efficiently.
Related Government Programs
- Department of Veterans Affairs Contracting
- Department of Veterans Affairs Programs
Risk Flags
- Vendor concentration risk.
- Potential for supply chain disruptions.
- Market volatility in pharmaceutical pricing.
- Dependence on a single delivery order for a critical service.
- Lack of transparency in the specific procurement method.
Tags
department-of-veterans-affairs, delivery-order, billion-dollar
Frequently Asked Questions
What is this federal contract paying for?
Department of Veterans Affairs awarded $1.12 billion to MCKESSON CORPORATION. EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2025 JULY
Who is the contractor on this award?
The obligated recipient is MCKESSON CORPORATION.
Which agency awarded this contract?
Awarding agency: Department of Veterans Affairs (Department of Veterans Affairs).
What is the total obligated amount?
The obligated amount is $1.12 billion.
What is the period of performance?
Start: 2025-07-01. End: 2025-07-31.
What is the historical performance of McKesson Corporation with the VA for similar pharmaceutical prime vendor services?
Historical performance data is crucial for assessing McKesson's reliability and efficiency in fulfilling VA pharmaceutical needs. Past contract adherence, delivery timeliness, product quality, and responsiveness to issues provide strong indicators of future performance. Reviewing past performance reviews and any documented disputes or commendations would offer valuable insights into their capabilities and potential risks.
How does the per-unit cost of pharmaceuticals under this contract compare to market rates and other federal contracts?
Comparing per-unit costs against market benchmarks and similar federal contracts (e.g., through GSA schedules or other agency contracts) is essential for value assessment. Significant deviations could indicate either exceptional value or potential overpayment. Understanding the pricing structure, including any volume discounts or rebates, is also key to a comprehensive cost analysis.
What are the contingency plans in place if McKesson Corporation faces disruptions in its supply chain or operational capabilities?
Contingency planning is vital given the critical nature of pharmaceutical supply. The VA should have robust plans to address potential disruptions, such as natural disasters, labor strikes, or financial instability affecting McKesson. This includes identifying alternative suppliers or distribution channels and ensuring continuity of care for veterans.
More Contracts from Mckesson Corporation
- Express Report: Pharmaceutical Prime Vendor (ppv)fy2026 November — $1.4B (Department of Veterans Affairs)
- Express Report: Pharmaceutical Prime Vendor (ppv)fy2026 October — $1.2B (Department of Veterans Affairs)
- Express Report: Pharmaceutical Prime Vendor (ppv)fy2025 September — $1.2B (Department of Veterans Affairs)
- Express Report: Pharmaceutical Prime Vendor (ppv)fy2026 December — $1.1B (Department of Veterans Affairs)
- Express Report: Pharmaceutical Prime Vendor (ppv)fy2026 January — $1.1B (Department of Veterans Affairs)
Other Department of Veterans Affairs Contracts
- CCN Region 3 Express Report — $5.2B (Optum Public Sector Solutions, Inc.)
- Express Report for FY22 Region 2 — $5.1B (Optum Public Sector Solutions, Inc.)
- Fiscal Year 2022 Express Report for Region 1 — $4.2B (Optum Public Sector Solutions, Inc.)
- Express Report for the Patient Centered Community Care (PC3) Contract — $3.3B (Triwest Healthcare Alliance Corp)
- CCN Region Three FY21 Express Report — $3.1B (Optum Public Sector Solutions, Inc.)